Skip to main content

Esophagus

Ausgabe 2/2022

Inhalt (19 Artikel)

Original Article

Maximum standardized uptake value change rate before and after neoadjuvant chemotherapy can predict early recurrence in patients with locally advanced esophageal cancer: a multi-institutional cohort study of 220 patients in Japan

Kentaro Murakami, Naoya Yoshida, Yusuke Taniyama, Kozue Takahashi, Takeshi Toyozumi, Takashi Uno, Takashi Kamei, Hideo Baba, Hisahiro Matsubara

Original Article

Novel pathological staging for patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by surgery

Junya Oguma, Koshiro Ishiyama, Daisuke Kurita, Kyohei Kanematsu, Yusuke Fujii, Kentaro Kubo, Shun Yamamoto, Yoshitaka Honma, Ken Kato, Hiroyuki Daiko

Original Article

Safety and feasibility of esophagectomy following combined neoadjuvant immunotherapy and chemotherapy for locally advanced esophageal cancer: a propensity score matching

Zhi-Nuan Hong, Zhenyang Zhang, Zhen Chen, Kai Weng, Kaiming Peng, Jiangbo Lin, Mingqiang Kang

Open Access Original Article

Outcomes of esophagectomy for patients with esophageal squamous cell carcinoma accompanied by recurrent laryngeal nerve palsy at diagnosis

Asako Ozaki, Shinji Mine, Kouhei Yoshino, Daisuke Fujiwara, Motomi Nasu, Tadasuke Hashiguchi, Takashi Hashimoto, Yoshiaki Kajiyama, Masahiko Tsurumaru, Atsushi Arakawa

Open Access Original Article

Survival impact of perioperative changes in prognostic nutritional index levels after esophagectomy

Ryoma Haneda, Yoshihiro Hiramatsu, Sanshiro Kawata, Junko Honke, Wataru Soneda, Tomohiro Matsumoto, Yoshifumi Morita, Hirotoshi Kikuchi, Kinji Kamiya, Hiroya Takeuchi

Open Access Original Article

Usefulness of wearable fitness tracking devices in patients undergoing esophagectomy

Junko Honke, Yoshihiro Hiramatsu, Sanshiro Kawata, Eisuke Booka, Tomohiro Matsumoto, Yoshifumi Morita, Hirotoshi Kikuchi, Kinji Kamiya, Keiko Mori, Hiroya Takeuchi

Original Article

Esophageal wall thickness on CT scans: can it predict the T stage of primary thoracic esophageal squamous cell carcinoma?

Yue Wang, Yong Huang, Qi-yu Zhao, Xiao-qin Li, Ling Wang, Ning-ning Wang, Jin-zhi Wang, Qing Wang

Original Article

Blue laser imaging identifies endoscopic findings corresponding to metachronous esophageal squamous cell carcinoma

Yuka Azuma, Osamu Dohi, Yuji Naito, Takeshi Yasuda, Takuma Yoshida, Tsugitaka Ishida, Hiroaki Kitae, Shinya Matsumura, Toshihumi Doi, Ryohei Hirose, Ken Inoue, Naohisa Yoshida, Kazuhiro Kamada, Kazuhiko Uchiyama, Tomohisa Takagi, Takeshi Ishikawa, Hideyuki Konishi, Ayako Nishimura, Mitsuo Kishimoto, Yoshito Itoh

Original Article

Telomere lengths in Barrett’s esophagus as a precancerous lesion

Junko Aida, Kaiyo Takubo, Michael Vieth, Horst Neuhaus, Mutsunori Fujiwara, Tomio Arai, Toshiyuki Ishiwata

Original Article

Biased expression of mutant alleles in cancer-related genes in esophageal squamous cell carcinoma

Masahiko Takahashi, Kazuyoshi Hosomichi, Hirofumi Nakaoka, Haruhito Sakata, Naoya Uesato, Kentaro Murakami, Masayuki Kano, Takeshi Toyozumi, Yasunori Matsumoto, Tetsuro Isozaki, Nobufumi Sekino, Ryota Otsuka, Itsuro Inoue, Hisahiro Matsubara

Original Article

Genomic analyses reveal SCN7A is associated with the prognosis of esophageal squamous cell carcinoma

Ping Yuan, Wenqing Rao, Zheng Lin, Shuang Liu, Xiuquan Lin, Chaofeng Wu, Xu Lin, Zhijian Hu, Weimin Ye

Original Article

Differences in upper esophageal sphincter function and clinical characteristics among the three subtypes of Japanese patients with esophageal achalasia

Ryo Katsumata, Noriaki Manabe, Maki Ayaki, Minoru Fujita, Jun Nakamura, Hirofumi Kawamoto, Yuusaku Sugihara, Hiroyuki Sakae, Kenta Hamada, Ken Haruma

Original Article

Efficacy and safety of peroral endoscopic myotomy in 100 older patients

Hiroki Okada, Hironari Shiwaku, Toshihiro Ohmiya, Akio Shiwaku, Suguru Hasegawa

Original Article

The treatment effects of acotiamide in esophagogastric outflow obstruction: a prospective longitudinal observational study

Eikichi Ihara, Haruei Ogino, Kazumasa Muta, Shohei Hamada, Masafumi Wada, Yoshitaka Hata, Hiroko Ikeda, Xiaopeng Bai, Yosuke Minoda, Mitsuru Esaki, Yoshimasa Tanaka, Takatoshi Chinen, Yoshihiro Ogawa

Original Article

Protective effect of rosuvastatin against the formation of benign esophageal stricture

Boqian Zhu, Bingzhan Song, Yanjuan Wang, Meiling Bao, Wenfang Cheng, Weifeng Zhang, Meihong Liu, Yaoyao Gong

Original Article

Saliva secretion is reduced in mild reflux esophagitis patients

Mai Koeda, Tomohide Tanabe, Yuichi Kitasako, Eri Momma, Yoshimasa Hoshikawa, Shintaro Hoshino, Noriyuki Kawami, Mitsuru Kaise, Katsuhiko Iwakiri

Original Article

Influence of laparoscopy-aided gastrostomy on gastroesophageal reflux in neurologically impaired patients using multichannel intraluminal impedance pH measurements

Daisuke Masui, Suguru Fukahori, Naoki Hashizume, Shinji Ishii, Naruki Higashidate, Yoshinori Koga, Saki Sakamoto, Shiori Tsuruhisa, Hirotomo Nakahara, Nobuyuki Saikusa, Yoshiaki Tanaka

Original Article

Determinants of reflux perception in patients with non-erosive reflux disease who have reflux-related symptoms on potassium-competitive acid blocker therapy

Noriyuki Kawami, Shintaro Hoshino, Yoshimasa Hoshikawa, Tomohide Tanabe, Mai Koeda, Eri Momma, Nana Takenouchi, Yuriko Hanada, Mitsuru Kaise, Katsuhiko Iwakiri

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.